LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)
Close on Nov 17, 2026Market cap $109.97MP/E –Yield –
LENZ Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
For fiscal 2025 it was 97.8%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 97.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 94.9% | – |
| Q1 FY2026 | Mar 31, 2026 | 43.4% | – |
| Q2 FY2025 | Jun 30, 2025 | 100.0% | – |
See a number that looks wrong?